USADA Leaves the UFC: Eighteen Months and the Files Nobody Published

On 11 October 2026, USADA issued a statement confirming it would end its partnership with the UFC after eight years, effective 1 January 2026. Three days earlier, a former two-division champion re-entered the random testing pool. Under the six-month rule, his eligibility date was set for early April 2026. No UFC statement mentioned that date. It sits in an internal file listing athlete name, sample code and collection date, the kind of file the promoter keeps and does not publish.

I read the USADA statement three times that evening. The notable part was not the sentence announcing the end of the partnership; it was the absence of any line saying who would take over the whereabouts database covering the entire active roster. Eighteen months later, writing this, I still cannot find a published table showing how many times each UFC athlete was tested in 2026.

The programme USADA ran from 2026 was the first time a mixed martial arts organisation outsourced every stage of testing, instead of leaving it to individual state athletic commissions within their own borders. Technically, that model solved an obvious gap: an athlete competing on five continents in a single year makes state-by-state testing meaningless.

The landmark cases all came from that period. In April 2026, USADA announced TJ Dillashaw had tested positive for recombinant erythropoietin, a two-year suspension backdated to 20 January 2026, and the fighter had already vacated the bantamweight title before the result became public. In July 2026, Brock Lesnar tested positive for clomiphene after UFC 200, received a one-year suspension, and the bout result was overturned to a no contest. In July 2026, Jon Jones tested positive for turinabol at UFC 214; the result was overturned, arbitration closed with a 15-month sanction, and he returned to competition in late 2026.

From 1 January 2026, Drug Free Sport International operates the new programme. That organisation has worked with the NFL, the NBA, MLB and the US college system. The UFC kept the six-month rule for athletes returning from retirement or from outside the testing pool. Running in parallel is another file: in March 2026, the UFC agreed to pay USD 335 million to settle the Le v. Zuffa antitrust case, filed in December 2026, alleging long-term exclusive contracts and commercial pressure that suppressed fighter pay.

Both files answer the same question: who holds final decision-making power in a sport where the promoter pays the wages, stages the events and signs the contract with the testing agency.

Four control points determine whether an anti-doping programme is genuinely independent, and all four sit in the contract rather than in the announcement. First, who signs with the sample collection officers and who schedules the collections. Second, whose servers hold the athletes whereabouts data, and who can access it. Third, who grants therapeutic use exemptions for prohibited substances, and whether those exemptions are published in aggregate. Fourth, who issues the final ruling and who decides whether the sanction is made public.

USADA held all four, but held them under a contract signed and funded by the UFC. When that contract expired, all four points transferred under the new agreement. What changed was the name on the paperwork. What stayed the same is that the party paying the bill still sits at the table when the next renewal is negotiated.

Two layers of a single test need separating here. The first layer is the laboratory. Urine and blood samples arrive with a string of characters and no name attached. The analyst does not know whether the donor is a champion or someone who signed a first contract last month. The lab does not know the athlete's name. That is why I trust them. Sample chain of custody, storage temperature, seal numbers and transport times are facts that cross-check against each other and are extremely hard to falsify at scale.

The second layer is administrative, and that is the narrow point. It decides who enters the testing pool, who leaves it, how dense or sparse the schedule is, which samples get extra analysis, which results get published, and when. An athlete clean in every sample can still lose two years of a career to an administrative decision about timing; in the other direction, a positive file can sit in a drawer until the statute of limitations expires. The bottleneck in combat sports anti-doping is not testing science, it is the paperwork held by the party paying the bill.

The six-month rule makes this explicit. It existed before 1 January 2026, it existed after, and it survived the change of operator untouched. It belongs to no scientist and to no state commission. It is a clause in a document drafted between the promoter and the testing agency. The same logic applies to therapeutic use exemptions: the number granted across the eight USADA years, the substances involved, the validity windows, none of it has been published in aggregate for outside verification. I asked three separate industry sources for those figures. None had them.

The money trail shows the same architecture. The USD 335 million in Le v. Zuffa is a class settlement, not an individually determined award; after legal fees, the remainder is distributed by number of bouts and career earnings, so a flat per-fighter division is only illustrative. Its scale nonetheless measures a labour market that was underpriced for years. TKO Group Holdings reported UFC revenue of roughly USD 1.29 billion for 2026. The plaintiffs in the antitrust case put fighter pay at around 20 percent of revenue, against roughly 50 percent in the largest US professional leagues. That is the plaintiffs estimate filed with the court, and it stands until the defendant publishes the actual split.

The legal framework explains why the actual split does not appear. Professional boxing in the United States has been governed since 2026 by the Muhammad Ali Boxing Reform Act, which includes disclosure obligations covering certain financial information between promoters and fighters. Mixed martial arts falls outside that scope. Bills extending the coverage to MMA have been introduced in the US Congress repeatedly and have never passed. With no statutory disclosure duty and no fighters union bargaining collectively, every clause, from test frequency to revenue share, is signed individually between one athlete and the promoter. An individual contract can be renegotiated or terminated; a collective clause has to be published.

Based on my years of following fights and testing files, most public debate stops at the question of which body is collecting samples. That question matters less than three contractual ones: where the testing budget comes from, who can access whereabouts data, and who signs the final ruling. A well-regarded body funded by the promoter still sits inside the same structure. A lesser-known body funded from an independent pool, obligated to publish aggregate data and not subject to promoter-appointed adjudicators, is different in kind.

There is a fair case for the 2026 change. USADA was never structurally independent: funded by the UFC, contracted by the UFC, and itself running equivalent programmes for other leagues on fixed-term deals. Moving to an operator already working with the NFL, the NBA and MLB standardises procedure, cuts administrative cost and brings MMA closer to the mainstream of US professional sport. If the benchmark is a testing body that takes no money from the promoter, both eras fail. The 2026 change created no new conflict; it removed a layer of reputational cover and forces observers to read the contract instead of the letterhead.

The second argument deserves more attention and gets less. The burden of random testing is not distributed evenly. An athlete in the pool must file a whereabouts location for every day of the next three months, with a fixed one-hour window to be available, and three filing failures are enough for a sanction without a single positive sample. The stadium is clean. The locker room is not. A fighter earning 12,000 dollars to win and 12,000 to lose carries exactly the same administrative load as a champion on a seven-figure purse, while the first also pays coaching fees, travel and gym costs out of the same money. That cost is not paid in cash, so it appears on nobody balance sheet, and nobody negotiates it on their behalf.

Three months chasing this file, I needed one line in the contract: the line naming the funding source. That line determines everything else, from annual test volume to whether a positive sample is published before or after the career of the person involved has already ended.

If this industry wants a testing standard it can be held to, it should publish five data sets each year: samples collected, samples per athlete, therapeutic use exemptions granted with substances named, adjudications with the composition of the ruling panel, and the funding source of the operator. None of those requires more than a spreadsheet. The next UFC US media rights deal, if it carries a line funding independent testing, will be the first readable signal after eighteen months. If no such line exists, every claim about a clean sport remains a claim, and the athletes remain the only party signing their name to the bill.